Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × brolucizumab × CNS × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neurofibromatosis 2 1 Macular Degeneration 1

Interventions

Temozolomide 110 Bevacizumab 42 Radiotherapy 41 Lomustine 22 Radiation 18 Irinotecan 15 Carboplatin 14 Nivolumab 13 Granulocyte-Macrophage Colony-Stimulating Factor 13 Cyclophosphamide 11 pembrolizumab 10 Trastuzumab 10 Capecitabine 10 paclitaxel-Angiopep-2 conjugate 8 dabrafenib 8 Surgical Procedures, Operative 8 TIC10 compound 7 Carmustine 7 Aminolevulinic Acid 7 3-Iodobenzylguanidine 7 trametinib 6 Topotecan 6 Paclitaxel 6 NVP-BKM120 6 IL13-PE38 6 Flucytosine 6 AZD 6244 6 vorasidenib 5 vocimagene amiretrorepvec 5 tovorafenib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03710564 2023-01-30

MERLIN

Novartis

Phase 3 Terminated

535 enrolled 14 charts

Macular Degeneration, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡